"At this time, we have not found any causal relationship with vaccination, and we are continuing our investigation and analysis of these cases," said the US Food and Drug Administration.
The United States Food and Drug Administration (FDA) indicated this Friday that at the moment, there is no established causal relationship between the vaccine against covid-19 from the pharmaceutical company Johnson & Johnson and the cases of people who suffered blood clots.
"At this time, we have not found any causal relationship with vaccination, and we are continuing our investigation and analysis of these cases," the regulator said in a statement.
The FDA acknowledged reports of "some individuals" who suffered thrombi and low blood platelets after receiving the vaccine.
"Both conditions can have different causes," said the FDA. We're going to keep the public notified because we have more data.
The European Medicines Agency (EMA) said Friday that it is investigating a possible link between the J&J compound and cases of clots. "One case occurred in a clinical trial, and three occurred during vaccination in the United States. One of them was fatal", indicated the EMA.
The FDA noted that the European agency's statement was based on information from it.
The J&J vaccine - which is administered in one dose - was authorized for emergency use in the United States in late February, after the regulator gave the green light to immunizers from pharmaceutical companies Pfizer / BioNTech and Moderna.
Manufacturing issues in Baltimore
On the other hand, next week, Johnson & Johnson will reduce by 80% the number of vaccines it will deliver in the US after the production problems it has registered in a Baltimore plant. According to figures from the Centers for Disease Control and Prevention (CDC, in English), the federal government has assigned just 700,000 J&J vaccines to the country's various states, a figure drastically lower than the 4.9 million this week.
The decline will complicate the mass vaccination campaign that is being carried out in the US, where the number of people who are candidates to receive doses is constantly increasing since, in more than 30 states, vaccines have been opened to all adults over 16 years of age.
J&J is expected to deliver a relatively low weekly amount of doses until it gets authorization from the US authorities of a Baltimore plant production company that has been having problems, confirmed this Friday in a press conference the coordinator of the White House Covid-19 Response, Jeff Zients.
Apparently, at the facility, owned by Emergent BioSolutions, ingredients from the J&J and AstraZeneca vaccine were "accidentally" mixed in mid-March, spoiling up to 15 million Johnson & Johnson doses and forcing the regulatory authorities to delay the authorization of the factory's production lines.
The same plant produces both doses of the J&J formula and the pharmaceutical AstraZeneca to fight covid-19.
However, the supply problems will not affect the European Union since that region uses a supply chain independent from that of the US.